Daily News Podcast

Cardiovascular risk with diclofenac


 

Diclofenac has emerged as a clear culprit in higher risk for adverse cardiovascular events. Also today, the majority of e-cigarette users are under 35 years of age, a hospital dropped length of stay for neonatal abstinence syndrome, and physician groups continue to call for CMS to drop evaluation and management proposal.
Amazon Alexa
Apple Podcasts
Spotify

Recommended Reading

Is it time for PCPs to take over chronic HCV?
MDedge Neurology
Rivaroxaban data abound at ESC 2018
MDedge Neurology
New MI definition for infarction vs injury
MDedge Neurology
Lorcaserin shows cardiovascular safety
MDedge Neurology
Lung function decline linked to cardiovascular risk
MDedge Neurology
Rivaroxaban beats aspirin for VTE
MDedge Neurology
New and Noteworthy Information—September 2018
MDedge Neurology
FDA approval for 2 HIV drugs
MDedge Neurology
ATTR-ACT shows treatment breakthrough in amyloid cardiomyopathy
MDedge Neurology
Modest alcohol and NAFLD
MDedge Neurology